ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Lapatinib mitigates acetic acid-induced ulcerative colitis and hepatic damage in rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is an inflammatory condition of the colon. In some cases, current treatments produce no response or may not be enough for remission, fostering a need for more effective medications. Tyrosine kinase inhibitors have shown to be effective in some inflammatory diseases. This study aimed to investigate the potential protective effect of lapatinib (LAP), a dual tyrosine kinase inhibitor, against acetic acid (AA)-induced UC in rats. Four groups were formed from twenty-four rats (6 rats each) as control, AA, AA + LAP (50 mg/kg) and AA + LAP (75 mg/kg). LAP (50 or 75 mg/kg/day) was administered orally for 7 days prior to induction of UC. On the 8th day, UC was induced by instillation of AA (4%) intrarectally. The rats were sacrificed 1 day following UC induction, colons and livers were collected for biochemical, histopathological and immunohistochemical examination. LAP markedly alleviated histological damage of both the colon and the liver. LAP effectively reduced the oxidative stress status by diminishing MDA, upregulating GSH and Nrf2 contents and enhancing SOD activity in colonic and hepatic tissues. Mechanistically, LAP significantly suppressed NF-κB p65 and TNF-α, pJAK2, pSTAT3 and the proinflammatory cytokines IL-17 and IL-23. Additionally, it decreased apoptosis by downregulating caspase-3 expression in colonic and hepatic tissues. Conclusion: LAP prevented AA-induced colitis and associated hepatic damage in rats, at least partially, via targeting IL-23/IL-17/JAK2/STAT3 axis., inhibiting NF-κB/TNF-α pathway, enhancement of Nrf2-mediated antioxidant defense, and suppression of caspase-3-dependent apoptosis.
Indexed as
Identifiers
42458002What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.